Adeshwar Meditex Quarterly Results for Trading Insights
In 2026, Adeshwar Meditex (ADESHWAR) reported revenue ₹30 Cr and net profit ₹1 Cr. Also explore Adeshwar Meditex share price performance to track price trends across different timeframes.
ADESHWAR Quarterly Results — Revenue, Profit & EPS Highlights
Adeshwar Meditex latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse ADESHWAR income statement for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹84 Cr in March 2025 (+0.0% vs March 2025, +5.0% vs March 2024)
- Net Profit of ₹2 Cr in March 2025 (+0.0% vs March 2025, +0.0% vs March 2024)
- EBITDA of ₹5 Cr in March 2025 (+0.0% vs March 2025)
- Operating Margin of 5.0% in March 2025 (+0.0pp vs March 2025)
- Earnings Per Share of ₹1.43 in March 2025 (+0.0% vs March 2025)
Adeshwar Meditex Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ADESHWAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 30 | 84 | 80 | 83 | 65 | -64.3% | - |
| Net Profit (₹ Cr) | 1 | 2 | 2 | 2 | 1 | - | - |
| EBITDA (₹ Cr) | 3 | 5 | 5 | 6 | 4 | - | - |
| EPS (₹) | 1.30 | 1.43 | 1.43 | 1.44 | 0.55 | - | - |
| Operating Margin (%) | 5.0% | 5.0% | 6.0% | 6.0% | 5.0% | - | - |
ADESHWAR Share Price Trend — 1-Year Movement Across Quarterly Results
Adeshwar Meditex 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit ADESHWAR screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ADESHWAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Adeshwar Meditex latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹477,587.63 Cr | 1951.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 172.7 |
|
Divis Laboratories
Mar 2026 |
₹227,904.78 Cr | 8349.0 | 2,986 | 751 | -5.0% | - | 25.2% | 294.9 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4956.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 430.6 |
|
Cipla
Mar 2026 |
₹117,848.47 Cr | 1477.0 | 6,612 | 543 | -9.3% | - | 8.2% | 215.0 |
|
Zydus Life Science
Mar 2026 |
₹112,798.83 Cr | 1108.0 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
All amounts in ₹ Crores